I’m excited about this merger and, after the close of the deal, look forward to joining Ian and Pfizer in a newly created role as President and Chief Operating Officer. Paul Bisaro and I will also take seats on Pfizer’s board of directors following the close. It will be a great opportunity to preserve the special attributes we have created at Allergan and bring them to a much bigger platform as part of Pfizer.
Following the close, I expect that many Allergan leaders will continue to have important roles in the combined company. However, as with our previous integrations, those leaders and their positions will be announced at a later date.
With annual sales of nearly $70 billion, global reach in 180 countries, more than 100 projects in mid-to-late stage development and $25 billion in annual cash flows beginning in 2018, we will have the opportunity to change health care on an even bigger scale than we could as Allergan alone.